Breaking News Instant updates and real-time market news.

GREK

Global X MSCI Greece ETF

$9.90

(0.00%)

, VIPS

Vipshop

$8.44

(0.00%)

09:40
12/18/17
12/18
09:40
12/18/17
09:40

Unusually active option classes on open December 18th

Unusual total active option classes on open include: GlobalFTSE Greece (GREK), Vipshop (VIPS), Tiffany (TIF), Deutsche Bank (DB), CSX (CSX), Northern Dynasty (NAK), Marathon Oil (MRO), Vale (VALE), UNG (UNG), and AMD (AMD).

GREK

Global X MSCI Greece ETF

$9.90

(0.00%)

VIPS

Vipshop

$8.44

(0.00%)

TIF

Tiffany

$101.34

(0.00%)

DB

Deutsche Bank

$19.43

(0.00%)

CSX

CSX

$52.93

-4.38 (-7.64%)

NAK

Northern Dynasty

$2.16

(0.00%)

MRO

Marathon Oil

$15.01

(0.00%)

VALE

Vale

$11.17

(0.00%)

UNG

United States Natural Gas Fund

$5.22

(0.00%)

AMD

AMD

$10.29

0.16 (1.58%)

  • 15

    Feb

GREK Global X MSCI Greece ETF
$9.90

(0.00%)

VIPS Vipshop
$8.44

(0.00%)

11/24/17
11/24/17
DOWNGRADE

Vipshop downgraded to Hold from Buy at ICBCI
ICBCI analyst Vicky Wu downgraded Vipshop to Hold and cut her price target for the shares to $9.50 from $9.80.
12/18/17
DAIW
12/18/17
UPGRADE
DAIW
Buy
Vipshop upgraded to Buy from Hold at Daiwa
10/30/17
10/30/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sotheby's (BID) initiated with a Buy at Aegis. 2. Alnylam (ALNY) initiated with a Buy at FBR Capital. 3. Adamas Pharmaceuticals (ADMS) initiated with an Outperform at Evercore ISI. 4. Vipshop (VIPS) initiated with a Neutral at UBS. 5. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/17
JPMS
11/22/17
NO CHANGE
Target $10
JPMS
Overweight
Vipshop price target lowered to $10 from $13 at JPMorgan
JPMorgan analyst Alex Yao lowered his price target for Vipshop to $10 saying "weak" user growth in Q3 is the result of light marketing spend. He expects the company's revenue growth to decelerate to 18% in 2018 due to elevated competition in the apparel vertical. User growth will likely remain soft, but average revenue per user should continue to drive revenue growth, Yao tells investors in a research note. He maintains an Overweight rating on Vipshop citing valuation.
TIF Tiffany
$101.34

(0.00%)

12/14/17
SBSH
12/14/17
UPGRADE
Target $115
SBSH
Buy
Tiffany upgraded to Buy from Neutral at Citi
Citi analyst Paul Lejuez upgraded Tiffany to Buy and raised his price target for the shares to $115 from $92. The shares look attractive as currency tailwinds and tax reform should benefit the company's earnings, Lejuez tells investors in a research note. Further, the analyst sees increasing probability that Tiffany could become a takeover target of a European luxury conglomerate. He believes provides a "backstop" for the shares and results in a favorable risk/reward.
12/14/17
12/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company's "strong brand and product pipeline have enabled it to raise prices and increase sales of both its apparel and footwear." 2. Tiffany (TIF) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying the shares look attractive as currency tailwinds and tax reform should benefit the company's earnings. 3. lululemon (LULU) upgraded to Buy from Hold at Deutsche Bank with analyst Paul Trussell saying the shares are only up 8% in the last 12 months and flat over the last five years. 4. Southwest (LUV) upgraded to Overweight from Neutral at Atlantic Equities with analyst Lindsay Bettiol saying he believes the company has a number of structural benefits when compared with legacy peers and he sees material upside to its free cash flow in coming years. 5. BioMarin (BMRN) upgraded to Outperform from Neutral at Wedbush with analyst Liana Moussatos citing recent events, namely Valoctocogene Roxaparvovec gene therapy for severe Hemophilia A being in the lead and emerging as a potential single dose cure with recent data at ASH and published in the NEJM, increasing sales projections for BMN 270 and value for BioMarin, sale of a second PRV, near-term non-GAAP breakeven, and her view that a company selling FVIII for Hemophilia A may be willing to pay a premium for a commercial license or for BioMarin as BMN 270 could be a serious threat to the multi-billion dollar worldwide FVIII franchise. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/01/17
12/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. VMware (VMW) upgraded to Outperform from Market Perform at BMO Capital with analyst Keith Bachman saying the company is benefiting from improved on-premise spending trends, increasing his projections for the overall fiscal 2019 computing spend to grow 3% versus prior forecast of 1%-2% decline. 2. Tiffany (TIF) upgraded to Overweight from Sector Weight at KeyBanc with analyst Edward Yruma saying he believes the positive 1% Americas comp in third quarter points to the early stages of a more broad-based sales recovery. 3. Mellanox (MLNX) upgraded to Buy from Neutral at Longbow with analyst Mike Burton saying he believes activist Starboard's involvement could lead to the company being acquired in whole or in pieces, and a reduction in OPEX levels more consistent with peers. 4. Agco (AGCO) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Jerry Revich saying to position for the next leg of the Machinery recovery, he prefers exposure to agriculture over trucks. 5. Vantiv (VNTV) upgraded to Outperform from Neutral at Wedbush with analyst Moshe Katri saying its Worldpay acquisition provides exposure to the U.K. and APAC, which are high-growth, potentially more profitable regions, while also drastically reducing its national merchants exposure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/17
JPMS
12/18/17
INITIATION
Target $103
JPMS
Neutral
Tiffany initiated with a Neutral at JPMorgan
JPMorgan analyst Matthew Boss started Tiffany with a Neutral rating and $103 price target. The analyst believes the new management's transition will take time.
DB Deutsche Bank
$19.43

(0.00%)

11/14/17
HSBC
11/14/17
UPGRADE
HSBC
Buy
Deutsche Bank upgraded to Buy from Hold at HSBC
HSBC analyst Alevizos Alevizakos upgraded Deutsche Bank to Buy and raised his price target for the shares to EUR 18 from EUR 14. The current valuation seemingly ignores the upside inherent in the bank's improved capital position, Alevizakos tells investors in a research note. The analyst believes excess capital creates optionality for the Deutsche.
11/14/17
11/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Outperform from Market Perform at Wells Fargo with analyst Bonnie Herzog saying the shares should be a core holding in 2018 and beyond. 2. Deutsche Bank (DB) upgraded to Buy from Hold at HSBC with analyst Alevizos Alevizakos saying the current valuation seemingly ignores the upside inherent in the bank's improved capital position. 3. Famous Dave's (DAVE) upgraded to Buy from Hold at Craig-Hallum with analyst Alex Fuhrman citing the third quarter results beat, refranchising efforts progressing well and further G&A reductions targeted. 4. ADP (ADP) resumed at Equal Weight, up from Underweight, at Morgan Stanley with analyst Danyal Hussain saying he expects ADP to execute with a greater sense of urgency, but there is still "more work to do" and the proxy fight has put a spotlight on some concerns on which investors will remain focused, including margins and potential share losses, he tells investors. 5. Phoenix New Media (FENG) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
KBWI
11/20/17
DOWNGRADE
KBWI
Underperform
Deutsche Bank downgraded to Underperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst George Karamanos downgraded Deutsche Bank to Underperform.
11/20/17
11/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler sayign valuation following "powerful" share appreciation now reflects the company's progress in growing earnings. 2. Five Below (FIVE) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba citing valuation. 3. Live Nation (LYV) downgraded to In Line from Outperform at Evercore ISI with analyst David Joyce citing valuation. 4. Monster Beverage (MNST) downgraded to Negative from Neutral at Susquehanna with analyst Pablo Zuanic citing its high valuation, which he believes is misplaced due to assumptions about an offer from Coca-Cola (KO). 5. Deutsche Bank (DB) downgraded to Underperform from Market Perform at Keefe Bruyette. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CSX CSX
$52.93

-4.38 (-7.64%)

12/18/17
JPMS
12/18/17
NO CHANGE
Target $63
JPMS
Overweight
CSX downside limited to $45-$48 per share, says JPMorgan
JPMorgan analyst Brian Ossenbeck believes Hunter Harrison's legacy will continue at CSX. The analyst reiterates an Overweight rating on the shares with a $63 price target following his death. He estimates downside in the stock is limited to $45-$48 based on his below consensus forecasts, with U.S. tax reform and a "tighter truck market" providing positive near term catalysts. CSX in premarket trading is down 2% to $51.61. The lack of a defined management succession plan remains a near term hurdle for CSX, however, and will not likely be addressed until the investor day in Q1 of 2018, Ossenbeck tells investors in a research note.
12/18/17
BARD
12/18/17
NO CHANGE
Target $58
BARD
Outperform
CSX shares should find support in $48-$50 level after CEO passing, says Baird
Baird analyst Benjamin Hartford noted the passing of CSX CEO Hunter Harrison and believes the shares should find support in the $48-$50 level, which is where shares traded during previous periods of transition for the company. While acknowledging his death adds incremental risk to the shares, Hartford maintained his Outperform rating and $58 price target on CSX.
12/18/17
SBSH
12/18/17
NO CHANGE
Target $58
SBSH
Buy
Harrison death may lead to CSX looking at Canadian Pacific merger, says Citi
The death of CEO Hunter Harrison may increase the likelihood of CSX (CSX) attempting to merge with Canadian Pacific (CP), Citi analyst Christian Wetherbee tells investors in a research note titled "The Passing of a Legend." The analyst, however, is not sure a deal could be accomplished due to elevated regulatory risk. Wetherbee thinks a "large portion of the heavy lifting" related to the start of CSX's turnaround occurred in 2017, allowing 2018 to be a year focused on executing. He still believes in the long-term potential of CSX. Jim Foote is capable of executing Hunter's vision, and CSX's board could move to add seasoned executives in the coming months, Wetherbee contends. He keeps a Buy rating on CSX with a $58 price target. The stock in premarket trading is down 2% to $51.62.
12/18/17
12/18/17
DOWNGRADE
Target $54

Hold
CSX downgraded to Hold from Buy at TD Securities
As previously reported, TD Securities downgraded CSX to Hold and cut its price target on the stock to $54 from $63 following the unexpected medical leave of absence and subsequent death of CEO Hunter Harrison, saying senior management now lacks a member with an operating background.
NAK Northern Dynasty
$2.16

(0.00%)

02/16/17
TDSI
02/16/17
UPGRADE
TDSI
Speculative Buy
Northern Dynasty upgraded to Speculative Buy from Hold at TD Securities
08/28/17
BMOC
08/28/17
INITIATION
BMOC
Market Perform
Northern Dynasty initiated with a Market Perform at BMO Capital
10/19/17
HCWC
10/19/17
INITIATION
Target $2.5
HCWC
Buy
Northern Dynasty initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Heiko Ihle started Northern Dynasty Minerals with a Buy rating and $2.50 price target. The benefits of the company's Alaska-based Pebble Project, despite permitting challenges, far outweigh its environmental risks, the analyst contends.
10/19/17
10/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Baker Hughes (BHGE) initiated with a Neutral at UBS. 2. Wayfair (W) initiated with a Buy at MKM Partners. 3. TerraForm Power (TERP) reinstated with a Neutral at JPMorgan. 4. Eiger BioPharmaceuticals (EIGR) initiated with a Buy at Roth Capital. 5. Northern Dynasty (NAK) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRO Marathon Oil
$15.01

(0.00%)

12/15/17
JPMS
12/15/17
UPGRADE
Target $15
JPMS
Neutral
Marathon Oil upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Michael Glick upgraded Marathon Oil to Neutral and raised his price target for the shares to $15 from $14. The analyst sees a more balanced risk/reward relative to the Exploration and Production large cap peer group at current share levels.
12/11/17
FBCO
12/11/17
INITIATION
FBCO
Outperform
Marathon Oil initiated with an Outperform at Credit Suisse
Credit Suisse analyst William Featherston initiated Marathon Oil with an Outperform rating and $20 price target.
12/05/17
ATLE
12/05/17
UPGRADE
ATLE
Overweight
Marathon Oil upgraded to Overweight from Neutral at Atlantic Equities
11/10/17
11/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. MetLife (MET) downgraded to Hold from Buy at Sandler O'Neill. 2. Johnson Controls (JCI) downgraded to Hold from Buy at Vertical Research with analyst Jeffery Sprague telling investors shares are "stuck in Purgatory." 3. Trovagene (TROV) downgraded to Hold from Buy at Maxim with analyst Jason Kolbert saying Trovagene needs to raise capital in order to gain a stronger position to transition to a therapeutics company focused on PCM-075. 4. Esterline (ESL) was downgraded to Hold from Buy at Drexel Hamilton and to Hold from Buy at SunTrust. 5. Marathon Oil (MRO) downgraded to Neutral from Buy at Citi with analyst Robert Morris citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VALE Vale
$11.17

(0.00%)

12/07/17
BMOC
12/07/17
NO CHANGE
Target $11
BMOC
Market Perform
Vale shares fully valued based on iron ore price outlook, says BMO Capital
BMO Capital analyst David Gagliano kept his Market Perform rating and $11 price target on Vale after the company's annual investor day. Gagliano says the company's 2018-22 outlook for iron ore prices is largely unchanged, anticipating a 6.8% rise next year. The analyst notes, however, that there is more downside than upside risk to iron ore prices, contending that Vale shares are "fully valued".
12/05/17
FBCO
12/05/17
UPGRADE
Target $15
FBCO
Outperform
Vale upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Ivano Westin upgraded Vale to Outperform and raised his price target for the shares to $15 from $9.50. Positive structural changes in China from supply reform and environmental control as well as Vale's focus on capital allocation, cost reduction, and sales volume optimization should drive the stock to new highs, Westin tells investors in a research note.
11/28/17
BTGP
11/28/17
UPGRADE
BTGP
Buy
Vale upgraded to Buy from Hold at BTG Pactual
11/27/17
MSCO
11/27/17
UPGRADE
Target $11.7
MSCO
Overweight
Vale upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Carlos De Alba upgraded Vale (VALE) to Overweight from Equal Weight, arguing that the market preference shown to Rio Tinto (RIO) should change as he projects Vale will generate more free cash flow in 2018-22 than Rio. The analyst, who also believes Vale's return on capital employed should exceed Rio Tinto's by the end of 2020, set an $11.70 price target on Vale shares.
UNG United States Natural Gas Fund
$5.22

(0.00%)

AMD AMD
$10.29

0.16 (1.58%)

12/18/17
MACQ
12/18/17
UPGRADE
Target $11
MACQ
Neutral
AMD upgraded to Neutral from Underperform at Macquarie
Macquarie analyst Srini Pajjuri upgraded AMD to Neutral and raised its price target to $11 from $10 saying expectations have been reset and downside is limited.
11/10/17
JEFF
11/10/17
NO CHANGE
Target $19
JEFF
Buy
Jefferies says good intellectual property makes AMD undervalued
In a research note titled "What's Good IP Going For These Days?," Jefferies analyst Mark Lipacis says recent acquisitions of semiconductor companies with good intellectual property, such as ARM, Mobileye and Linear Technology, have garnered enterprise-to-sales multiples of five to 27 times. With an enterprise-to-sales ratio of two times, AMD looks undervalued, Lipacis contends. He believes the company has a "unique" combination of intellectual property in x86 and GPUs. The analyst keeps a Buy rating on AMD with a $19 price target. The chipmaker closed yesterday down 59c to $11.12.
11/08/17
STFL
11/08/17
NO CHANGE
STFL
Stifel says Intel purported hiring of AMD exec furthers competition with Nvidia
Commenting on reports that Raja Koduri, the head of AMD's (AMD) Radeon Technologies Group, is leaving the company and speculation that he would join Intel (INTC), Stifel analyst Kevin Cassidy said that, if true, this news points toward Intel working to build a stronger GPU and general purpose parallel processor to compete with Nvidia (NVDA). The analyst, who said "Intel is clearly not going to let Nvidia run away with the AI market," views Intel's developing strategy as positive for AMD too.
11/29/17
GSCO
11/29/17
NO CHANGE
Target $10.4
GSCO
Sell
AMD losing share in multiple markets, says Goldman Sachs
Goldman analyst Toshiya Hari said Mercury's (MRCY) Q3 volume and pricing data indicates AMD (AMD) is losing shares. Hari lowered AMD 2019/20 earnings estimates by 11%/8%, respectively, due to disappointing market share performance across multiple markets. Hari views AMD's current risk/reward as negatively skewed and reiterates his Sell rating and lowered his price target to $10.40 from $11.40 on shares.

TODAY'S FREE FLY STORIES

CHCO

City Holding

$76.84

0.45 (0.59%)

07:37
07/19/18
07/19
07:37
07/19/18
07:37
Earnings
City Holding reports Q2 EPS $1.35, consensus $1.13 »

Return on assets and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:35
07/19/18
07/19
07:35
07/19/18
07:35
Hot Stocks
Alliance Data CEO says Q2 'marked the beginning of acceleration in our business' »

Ed Heffernan, president…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

MSFT

Microsoft

$105.08

-0.92 (-0.87%)

, DIS

Disney

$110.71

0.41 (0.37%)

07:35
07/19/18
07/19
07:35
07/19/18
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

MSFT

Microsoft

$105.08

-0.92 (-0.87%)

DIS

Disney

$110.71

0.41 (0.37%)

CZR

Caesars

$11.50

0.05 (0.44%)

RHT

Red Hat

$148.51

0.99 (0.67%)

OMC

Omnicom

$70.59

-0.1 (-0.14%)

FTI

TechnipFMC

$30.94

0.28 (0.91%)

ETFC

E-Trade

$63.14

2 (3.27%)

HLT

Hilton

$82.92

1.86 (2.29%)

BYD

Boyd Gaming

$37.89

-0.44 (-1.15%)

MT

ArcelorMittal

$30.99

0.665 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 25

    Jul

  • 26

    Jul

  • 26

    Jul

  • 01

    Aug

  • 07

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 04

    Sep

AMZN

Amazon.com

$1,842.36

-1.64 (-0.09%)

, FB

Facebook

$209.35

-0.64 (-0.30%)

07:35
07/19/18
07/19
07:35
07/19/18
07:35
Recommendations
Amazon.com, Facebook, Twitter analyst commentary  »

JPMorgan continues to…

AMZN

Amazon.com

$1,842.36

-1.64 (-0.09%)

FB

Facebook

$209.35

-0.64 (-0.30%)

TWTR

Twitter

$43.34

-1.36 (-3.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 26

    Jul

  • 27

    Jul

  • 16

    Aug

  • 18

    Sep

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:34
07/19/18
07/19
07:34
07/19/18
07:34
Earnings
Breaking Earnings news story on Alliance Data »

Alliance Data reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

07:33
07/19/18
07/19
07:33
07/19/18
07:33
Hot Stocks
Domino's Pizza reports Q2 domestic SSS up 6.9% »

Reports Q2 international…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Sep

  • 05

    Oct

MNK

Mallinckrodt

$21.81

0.19 (0.88%)

07:33
07/19/18
07/19
07:33
07/19/18
07:33
Recommendations
Mallinckrodt analyst commentary  »

Mallinckrodt price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 09

    Aug

  • 13

    Aug

  • 22

    Aug

STBA

S&T Bancorp

$43.96

0.19 (0.43%)

07:33
07/19/18
07/19
07:33
07/19/18
07:33
Earnings
S&T Bancorp reports Q2 EPS 61c, consensus 61c »

Reports Q2 NIM 3.64%.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

ONDK

On Deck Capital

$8.09

0.6 (8.01%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Downgrade
On Deck Capital rating change  »

Morgan Stanley sees On…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 15

    Aug

  • 16

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:32
07/19/18
07/19
07:32
07/19/18
07:32
Earnings
Breaking Earnings news story on Alliance Data »

Alliance Data backs FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Alliance Data backs FY18 core EPS view $22.50 to $23.00, consensus $22.57 »

CEO Heffernan continued:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

DPZ

Domino's Pizza

$283.74

1.74 (0.62%)

07:31
07/19/18
07/19
07:31
07/19/18
07:31
Earnings
Domino's Pizza reports Q2 adjusted EPS $1.84, consensus $1.75 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Sep

  • 05

    Oct

ADS

Alliance Data

$226.51

1.13 (0.50%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Earnings
Alliance Data reports Q2 core EPS $5.01, consensus $4.66 »

Reports Q2 revenue $1.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

LONE

Lonestar Resources

$10.37

0.42 (4.22%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Initiation
Lonestar Resources initiated  »

Lonestar Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

, FOXA

21st Century Fox

$46.69

0.22 (0.47%)

07:30
07/19/18
07/19
07:30
07/19/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

CMCSA

Comcast

$34.03

-0.23 (-0.67%)

FOXA

21st Century Fox

$46.69

0.22 (0.47%)

GM

General Motors

$39.87

-0.185 (-0.46%)

PZZA

Papa John's

$53.60

2.06 (4.00%)

HPQ

HP Inc.

$23.54

-0.06 (-0.25%)

GOGO

Gogo

$3.91

0.15 (3.99%)

MDR

McDermott

$17.97

-0.075 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 31

    Jul

SQ

Square

$68.30

-0.02 (-0.03%)

07:28
07/19/18
07/19
07:28
07/19/18
07:28
Upgrade
Square rating change  »

Square upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 15

    Aug

  • 16

    Aug

MEET

Meet Group

$4.14

0.08 (1.97%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Upgrade
Meet Group rating change  »

Meet Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$2.86

-0.1 (-3.38%)

07:26
07/19/18
07/19
07:26
07/19/18
07:26
Recommendations
Amarin analyst commentary  »

Amarin's Vascepa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$111.52

1.01 (0.91%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Upgrade
JPMorgan rating change  »

JPMorgan upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

EBAY

eBay

$37.95

0.13 (0.34%)

07:25
07/19/18
07/19
07:25
07/19/18
07:25
Recommendations
eBay analyst commentary  »

eBay price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FFIV

F5 Networks

$179.52

2.86 (1.62%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Downgrade
F5 Networks rating change  »

Morgan Stanley sees risk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 08

    Aug

CMG

Chipotle

$453.56

0.77 (0.17%)

, SBUX

Starbucks

$51.15

-0.12 (-0.23%)

07:24
07/19/18
07/19
07:24
07/19/18
07:24
Recommendations
Chipotle, Starbucks analyst commentary  »

Wedbush cautious on…

CMG

Chipotle

$453.56

0.77 (0.17%)

SBUX

Starbucks

$51.15

-0.12 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

PTCT

PTC Therapeutics

$35.02

-0.19 (-0.54%)

07:23
07/19/18
07/19
07:23
07/19/18
07:23
Initiation
PTC Therapeutics initiated  »

PTC Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$37.75

-0.35 (-0.92%)

07:22
07/19/18
07/19
07:22
07/19/18
07:22
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTB

M&T Bank

$174.38

5.77 (3.42%)

07:20
07/19/18
07/19
07:20
07/19/18
07:20
Recommendations
M&T Bank analyst commentary  »

M&T Bank price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.